Aflac Incorporated reported solid fourth quarter 2025 results with adjusted earnings per diluted share of $1.57, up 0.6% year-over-year, and full-year adjusted EPS of $7.49. The company demonstrated strong top-line performance, particularly in Japan where sales increased 15.7% in Q4 and 16% for the full year, driven significantly by the new Miraito cancer insurance product (+35.6% sales increase). In the U.S., new annual sales reached nearly $1.6 billion, with net earned premiums growing 2.9% for the year. Capital deployment was a major highlight, as Aflac returned a record $4.8 billion to shareholders in 2025 through $3.5 billion in share repurchases and $1.2 billion in dividends, while also announcing a 5.2% dividend increase for Q1 2026. Looking ahead to 2026, management expects underlying earned premiums in Japan to decline 1% to 2% but forecasts pretax margin expansion to 33%–36%, while the U.S. segment anticipates premium growth at the lower end of 3%–6% with pretax margins of 17%–20%.
| Metric | Value | Change |
|---|---|---|
| Q4 Adjusted EPS | $1.57 | +0.6% year-over-year |
| Full Year Adjusted EPS | $7.49 | Strong growth driven by Japan sales and investment income |
| Japan Sales Growth (Q4) | 15.7% | Driven by 35.6% increase in cancer insurance (Miraito) |
| Japan Persistency | 93.1% | Remained strong year-over-year |
| U.S. Net Earned Premiums (FY) | N/A (Growth 2.9%) | +2.9% year-over-year |
| Adjusted ROE (ex-FX) | 14.5% | Solid spread to cost of capital |
| Share Repurchases (FY 2025) | $3.5 billion | Record high; 33 million shares repurchased |
| Japan Pretax Margin (Q4) | 31.3% | -30 bps year-over-year |
| U.S. Benefit Ratio (Q4) | 48.6% | +230 bps year-over-year |
Aflac is successfully pivoting its product portfolio in Japan to combat rising interest rates and changing consumer needs. The launch of 'Miraito' drove a 35.6% increase in cancer insurance sales, while the repricing of the savings product 'Tsumitasu' aims to capture demand for asset formation among younger demographics. This strategic shift is critical as it allows Aflac to maintain high sales volumes (+16% YoY) despite a challenging rate environment, ensuring the company remains competitive in the third sector.
The U.S. segment is undergoing a strategic transformation, diversifying away from traditional voluntary benefits toward higher-growth areas like Group Life and Disability, Network Dental, and Vision. Management reported that Group sales grew 14% overall, with Network Dental up 48.8%. While the traditional voluntary block remains profitable but flat, this mix shift supports long-term growth, though it pressures near-term benefit ratios.
Capital management remains a core competitive advantage, with Aflac deploying a record $4.8 billion to shareholders in 2025. The creation of $2 billion in off-balance sheet precapitalized trusts (PCAPs) enhanced liquidity flexibility, allowing the company to lower its minimum holding company liquidity balance by $750 million. This financial engineering supports aggressive buybacks (33 million shares repurchased) and dividend growth, maximizing shareholder returns.
Aflac is optimizing its regulatory capital profile through active reinsurance and asset-liability management (ALM). The company has ceded 6% of its Japan balance sheet to its Bermuda entity (targeting 10%) and has reduced sensitivities to market risk factors. With an SMR over 970% and estimated ESR of 253%, Aflac possesses significant capital flexibility to withstand economic shocks and pursue strategic opportunities.
The company is integrating Artificial Intelligence to enhance operational efficiency rather than replace its workforce. In the U.S., over 60% of claims in the traditional business utilize automation for advice, while AI is streamlining the enrollment process. This focus on 'assistive' AI aims to improve the producer experience and claims adjudication speed without disrupting the high-touch service model that defines their brand.
Despite strong sales growth, Aflac faces persistent headwinds in Japan regarding net earned premium growth. Underlying earned premiums declined 1.2% in Q4 2025, and management guided for a further decline of 1% to 2% in 2026. This structural decline is driven by a massive in-force block where high persistency (93.1%) means new sales cannot yet offset the impact of paid-up policies and reinsurance, creating a long-tail drag on top-line revenue expansion.
Profitability metrics in the U.S. are showing signs of pressure. The Q4 benefit ratio increased 230 basis points year-over-year to 48.6%, driven by higher claims activity and prior year endorsements. Management guided for the 2026 U.S. benefit ratio to rise to the 48%–52% range, indicating that the shift toward higher-margin group products and the normalization of claims post-pandemic will likely compress margins compared to the unusually low levels seen in recent years.
Japan's benefit ratio guidance of 60%–63% for 2026, while improved, relies heavily on one-time accounting benefits. CFO Max Broden attributed a significant portion of this improvement to a 130 basis point reduction in the net premium ratio due to actuarial assumption updates and the runoff of high-ratio legacy 'waste' products. Investors should be cautious about assuming this level of margin improvement is sustainable once these transient factors normalize.
Rising yen interest rates present a dual risk of lapsation and lower hedging benefits. Management acknowledged that while lapses on the savings block are currently 'low and in line,' higher rates could incentivize surrenders. Furthermore, the uplift from the Undertaking Specific Parameter (USP) on the ESR ratio has dropped from 30 points to 18 points due to rising rates, reducing a key regulatory capital buffer slightly.
Overall: Management exhibited a high level of confidence and satisfaction throughout the call, frequently describing results as 'solid,' 'strong,' and 'pleasing.' There was a distinct focus on disciplined capital allocation and strategic product positioning, particularly regarding the successful launch of new products in Japan. The tone shifted to detailed analytical precision during the Q&A when discussing actuarial assumptions and interest rate sensitivities, but remained assured regarding the company's ability to navigate market volatility.
Confidence: HIGH - Management consistently used definitive language regarding their strategic execution ('We have put in place the right people and the strategy') and capital strength ('Our capital position remains strong'). The commitment to record share buybacks and dividend increases signals strong confidence in cash flow generation and underlying business stability.
Management expects a decline of 1% to 2%. This reflects the persistent headwind of the large in-force block where lapses are expected to exceed new sales despite strong product performance.
Guidance range is 33% to 36%, an improvement from Q4 2025 levels. This is supported by a lower benefit ratio expectation of 60% to 63%.
Expected to be at the lower end of the 3% to 6% range. Growth will be driven by Group and Dental/Vision lines offsetting a flat traditional voluntary block.
Expected range is 17% to 20%. This assumes a benefit ratio of 48% to 52%, reflecting higher claims and mix shift impacts.
Hedging & Uncertainty: Management employed moderate hedging, particularly regarding forward-looking guidance and interest rate impacts. Phrases such as 'if everybody is 100% efficient in their behavior, you would expect... lapsation to increase somewhat' and 'we estimate the impact... to be approximately' were used to qualify predictions about lapses and financial ratios. However, hedging was minimal regarding capital strength, with definitive statements like 'Our capital position remains strong.' The use of 'we believe' and 'we expect' was standard for guidance, but the specificity of the ranges provided (e.g., 60%–63% benefit ratio) suggests high conviction in the financial models.
We're somewhat the victim of very strong persistency. - Max Broden, CFO
We are not looking to replace the people. It's a high-touch business. - Virgil Miller, President of Aflac U.S.
We have deliberately improved our ALM during this time, which has led to reduced exposure to interest rate risk. - Max Broden, CFO
We generally have lowered our sensitivities to market risk factors. - Max Broden, CFO
We are operating in a relatively narrow niche... to find operational and strategic targets within those niches is relatively difficult. - Max Broden, CFO
We will continue to be flexible and tactical in the way we manage the balance sheet. - Max Broden, CFO
Analyst Sentiment: Analysts were inquisitive and focused heavily on the sustainability of margins and the mechanics of the Japan benefit ratio improvement. Questions from Wells Fargo, Piper Sandler, and Jefferies indicated a desire to understand the 'quality' of the earnings (e.g., GAAP vs. Statutory differences, one-time impacts). There was also skepticism regarding the lack of earned premium growth despite high sales, with analysts probing the timeline for an inflection point.
Management Responses: Management responses were detailed and transparent, particularly CFO Max Broden, who provided granular breakdowns of actuarial assumptions and product mix impacts. They did not deflect difficult questions about premium decline or benefit ratio inflation, instead explaining the mathematical drivers (e.g., runoff of legacy blocks, net premium ratio adjustments). This level of detail reinforced their credibility and command of the business fundamentals.
Japan Benefit Ratio Drivers: Analysts sought to understand if the margin improvement was sustainable or driven by one-time accounting changes. Management clarified that roughly 1/3 comes from permanent assumption updates and 2/3 from mix/runoff effects.
Interest Rate Sensitivity: Multiple questions focused on the impact of rising yen yields on lapses and capital. Management assured that ALM improvements have reduced risk and lapses remain within expectations.
U.S. Sales Mix vs. Total Growth: Analysts questioned why strong group sales (14%+) weren't translating to higher overall U.S. sales. Management explained that the traditional voluntary block is a large anchor that is currently flat to negative, masking the growth in new channels.
Capital Deployment & M&A: Questions arose regarding the use of excess capital given the strong balance sheet. Management emphasized that M&A is difficult in their 'niche' markets and that buybacks currently offer the best IRR.
Aflac presents a compelling investment case driven by its exceptional capital allocation strategy and robust return on equity (14.5% ex-FX). The company's management has demonstrated a disciplined approach to shareholder returns, deploying a record $4.8 billion in 2025 via buybacks and dividends while maintaining a fortress balance sheet with an SMR over 970%. The primary growth driver remains the Japan segment, where innovative product launches like Miraito are driving double-digit sales increases, even if top-line premium growth remains temporarily suppressed by the large in-force block dynamics. In the U.S., the strategic pivot into Group and Dental/Vision products provides a new growth vector, diversifying revenue beyond the mature voluntary market. Key success factors include: (1) Maintaining the strong persistency rates (93% in Japan) that stabilize cash flows; (2) Successful execution of the product repricing strategy to mitigate interest rate risk; (3) Sustained margin expansion in Japan to the 33-36% range as guided. Risks to monitor include the structural decline in Japan net earned premiums and the rising benefit ratio in the U.S. which could compress margins if claims experience worsens. However, the valuation appears supported by the aggressive share repurchase program and the company's ability to generate excess capital. The 43-year history of dividend increases underscores the reliability of the business model. Given the strong ROE relative to the cost of capital and the management's confident outlook for 2026 profitability, Aflac remains a solid holding for income and growth-oriented investors.
The transcript reveals a significant macroeconomic shift in Japan regarding consumer financial behavior, specifically the transition from simple savings to asset formation. Management noted that the government is promoting a shift 'from saving to investment,' and Aflac's product 'Tsumitasu' is designed to respond to citizens' needs for asset formation. This indicates a broader trend in Japan where consumers, particularly the young and middle-aged, are seeking yield and investment-linked insurance products due to rising interest rates and inflationary pressure.
The U.S. supplemental health market is experiencing a 'K-shaped' economic impact, though Aflac noted no material impact yet. Management highlighted that 22 million Americans were affected by ACA changes, driving activity in direct-to-consumer channels. This suggests a macro environment where volatility in employment and healthcare access is driving consumers to seek supplemental coverage outside traditional employer-sponsored groups, benefiting digital-first distribution models.